proxyvotesnow.com

Home › Companies › Dianthus Therapeutics, Inc. › 2025-2026

Dianthus Therapeutics, Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and Dianthus Therapeutics, Inc.’s Form 8-K, filed 2026-05-22 (Item 5.07 on EDGAR). Page generated 02 October 2026.

  • 5Ballot items
  • 265Asset managers
  • 1,667Fund votes
  • 2026-05-21Meeting date

Proxy season: 2024-2025 2025-2026

Explore Dianthus Therapeutics, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Dianthus Therapeutics, Inc.

These tallies are Dianthus Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-05-22 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Dianthus Therapeutics, Inc. — official shareholder meeting results, meeting held 2026-05-21
Ballot itemForAgainst AbstainWithheldBroker non-votesOutcome
Elect Director: Sujay Kango 42,739,315---- 479,1993,585,554 Majority: yes
Elect Director: Anne McGeorge 34,814,377---- 8,404,1373,585,554 Majority: yes
Elect Director: Jonathan Violin, Ph.D 42,799,946---- 418,5683,585,554 Majority: yes
Proposal 2: Advisory Vote on Executive Compensation The Company's stockholders approved, on an advisory basis, the compensation paid to the Company's named executive officers 41,004,5071,713,043500,964 --3,585,554 Majority: yes
Proposal 3: Ratification of Appointment of Independent Registered Public Accounting Firm The Company's stockholders ratified the appointment of Deloitte & Touche, LLP as the Company's independent registered public accounting firm for the fiscal year ending Dec 46,298,3195,279500,471 ---- Majority: yes

Source: Dianthus Therapeutics, Inc., Form 8-K, filed with the SEC on 2026-05-22 — read the filing on EDGAR.

How asset managers voted at the Dianthus Therapeutics, Inc. 2025-2026 meeting

Each item below shows how the 265 asset managers that disclosed a Dianthus Therapeutics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. To approve, on an advisory basis, the compensation paid to our named executive officers; and

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 8 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%
FOR: 41,004,507AGAINST: 1,713,043

Dianthus Therapeutics, Inc.’s own tally for this item (“Proposal 2: Advisory Vote on Executive Compensation The Company's stockholders approved, on an advisory basis, the compensation paid to the Company's named executive officers”): 41,004,507 for, 1,713,043 against, per its Form 8-K filed 2026-05-22 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 54,582,749 outstanding shares: 75% for, 3% against (78% of the company cast a for/against vote).

The 264 asset managers below cast 95% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.

FOR 94%
FOR: 94.0%AGAINST: 5.0%ABSTAIN: 1.0%NOT VOTED: 0.0%
Largest asset managers voting on “To approve, on an advisory basis, the compensation paid to our named executive officers; and” at Dianthus Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity11,085,6750 00For
Vanguard4,110,9843 10For
T. Rowe Price3,965,8850 00For
RA CAPITAL MANAGEMENT, L.P.2,611,7330 00For
Fairmount Funds Management LLC2,537,1910 00For
BlackRock2,152,9852,838 00For
Wellington2,136,3750 00For
Octagon Capital Advisors LP2,086,6670 00For
Polar Capital Holdings Plc1,900,0000 00For
Venrock Adviser, LLC1,180,0000 00For
AllianceBernstein1,178,2460 00For
FRED ALGER MANAGEMENT, LLC55,8731,097,202 00Against
FRANKLIN ADVISERS INC955,1050 00For
State Street917,6111,264 00For
GEODE CAPITAL MANAGEMENT, LLC736,5900 00For
Charles Schwab615,7580 00For
ALGER INSTITUTIONAL FUNDS0488,463 00Against
Catalio Capital Management, LP00 482,0000Abstain
Logos Global Management LP475,0000 00For
Citadel469,8010 00For
FRANKLIN STRATEGIC SERIES466,7840 00For
FARALLON CAPITAL MANAGEMENT, L.L.C.456,7110 00For
SILVERARC CAPITAL MANAGEMENT, LLC427,3940 00For
BRAIDWELL LP404,3250 00For
Cormorant Asset Management, LP393,1510 00For

Showing the 25 largest of 264 asset managers. See all 264 in the interactive database.

2. To elect Class II directors to our Board of Directors, to serve until the 2029 annual meeting of stockholders and until their successors have been duly elected and qualified, or until their earlier death, resignation or removal: Anne McGeorge

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

81% Majority: yes · of votes cast

FOR 81%WITHHELD 19%
FOR: 34,814,377WITHHELD: 8,404,137

Dianthus Therapeutics, Inc.’s own tally for this item (“Elect Director: Anne McGeorge”): 34,814,377 for, 8,404,137 withheld, per its Form 8-K filed 2026-05-22 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 54,582,749 outstanding shares: 64% for, 15% withheld (79% of the company cast a for/withheld vote).

The 82 asset managers below cast 100% of the shares they voted on this item FOR (12,685,923 for, 0 against).

FOR 79%ABSTAIN 21%
FOR: 12,685,923 (78.9%)ABSTAIN: 3,384,367 (21.1%)
Largest asset managers voting on “To elect Class II directors to our Board of Directors, to serve until the 2029 annual meeting of stockholders ” at Dianthus Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity4,800,1920 00For
Vanguard3,807,0550 4,6730For
T. Rowe Price828,8920 854,6980Abstain
BlackRock800,3330 00For
ALGER INSTITUTIONAL FUNDS00 488,4630Abstain
FRANKLIN STRATEGIC SERIES00 466,7840Abstain
State Street423,1230 1,1340For
Charles Schwab305,8830 00For
AllianceBernstein00 288,4170Abstain
ALGER FUNDS II00 230,3810Abstain
MUTUAL FUND SERIES TRUST225,2610 00For
Columbia Threadneedle220,1880 00For
Prudential/PGIM193,8880 16,1280For
AB DISCOVERY GROWTH FUND, INC.00 203,2480Abstain
TIAA196,5170 00For
Equitable89,3320 99,9240Abstain
ALGER FUNDS00 156,3410Abstain
Dimensional00 110,8940Abstain
Invesco90,1390 00For
Hartford79,2190 00For
American Century00 78,5320Abstain
Lord Abbett71,6350 00For
Principal00 65,1250Abstain
Russell Investments63,6440 00For
QUANTITATIVE MASTER SERIES LLC58,2660 00For

Showing the 25 largest of 82 asset managers. See all 82 in the interactive database.

3. To elect Class II directors to our Board of Directors, to serve until the 2029 annual meeting of stockholders and until their successors have been duly elected and qualified, or until their earlier death, resignation or removal: Jonathan Violin, Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

99.0% Majority: yes · of votes cast

FOR 99.0%
FOR: 42,799,946WITHHELD: 418,568

Dianthus Therapeutics, Inc.’s own tally for this item (“Elect Director: Jonathan Violin, Ph.D”): 42,799,946 for, 418,568 withheld, per its Form 8-K filed 2026-05-22 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 54,582,749 outstanding shares: 78% for, 0.8% withheld (79% of the company cast a for/withheld vote).

The 82 asset managers below cast 100% of the shares they voted on this item FOR (15,934,925 for, 0 against).

FOR 99.1%
FOR: 15,934,925 (99.2%)ABSTAIN: 135,365 (0.8%)
Largest asset managers voting on “To elect Class II directors to our Board of Directors, to serve until the 2029 annual meeting of stockholders ” at Dianthus Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity4,800,1920 00For
Vanguard3,808,5630 3,1650For
T. Rowe Price1,683,5900 00For
BlackRock800,3330 00For
ALGER INSTITUTIONAL FUNDS488,4630 00For
FRANKLIN STRATEGIC SERIES466,7840 00For
State Street423,6490 6080For
Charles Schwab305,8830 00For
AllianceBernstein288,4170 00For
ALGER FUNDS II230,3810 00For
MUTUAL FUND SERIES TRUST225,2610 00For
Columbia Threadneedle220,1880 00For
Prudential/PGIM209,6820 3340For
AB DISCOVERY GROWTH FUND, INC.203,2480 00For
TIAA196,5170 00For
Equitable189,2560 00For
ALGER FUNDS156,3410 00For
Dimensional00 110,8940Abstain
Invesco90,1390 00For
Hartford79,2190 00For
American Century78,5320 00For
Lord Abbett71,6350 00For
Principal65,1250 00For
Russell Investments63,6440 00For
QUANTITATIVE MASTER SERIES LLC58,2660 00For

Showing the 25 largest of 82 asset managers. See all 82 in the interactive database.

4. To elect Class II directors to our Board of Directors, to serve until the 2029 annual meeting of stockholders and until their successors have been duly elected and qualified, or until their earlier death, resignation or removal: Sujay Kango

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%
FOR: 42,739,315WITHHELD: 479,199

Dianthus Therapeutics, Inc.’s own tally for this item (“Elect Director: Sujay Kango”): 42,739,315 for, 479,199 withheld, per its Form 8-K filed 2026-05-22 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 54,582,749 outstanding shares: 78% for, 0.9% withheld (79% of the company cast a for/withheld vote).

The 82 asset managers below cast 100% of the shares they voted on this item FOR (15,938,903 for, 0 against).

FOR 99.1%
FOR: 15,938,903 (99.2%)ABSTAIN: 131,387 (0.8%)
Largest asset managers voting on “To elect Class II directors to our Board of Directors, to serve until the 2029 annual meeting of stockholders ” at Dianthus Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity4,800,1920 00For
Vanguard3,811,7270 10For
T. Rowe Price1,683,5900 00For
BlackRock800,3330 00For
ALGER INSTITUTIONAL FUNDS488,4630 00For
FRANKLIN STRATEGIC SERIES466,7840 00For
State Street424,2570 00For
Charles Schwab305,8830 00For
AllianceBernstein288,4170 00For
ALGER FUNDS II230,3810 00For
MUTUAL FUND SERIES TRUST225,2610 00For
Columbia Threadneedle220,1880 00For
Prudential/PGIM209,6820 3340For
AB DISCOVERY GROWTH FUND, INC.203,2480 00For
TIAA196,5170 00For
Equitable189,2560 00For
ALGER FUNDS156,3410 00For
Dimensional00 110,8940Abstain
Invesco90,1390 00For
Hartford79,2190 00For
American Century78,5320 00For
Lord Abbett71,6350 00For
Principal65,1250 00For
Russell Investments63,6440 00For
QUANTITATIVE MASTER SERIES LLC58,2660 00For

Showing the 25 largest of 82 asset managers. See all 82 in the interactive database.

5. TO RATIFY THE APPOINTMENT OF DELOITTE & TOUCHE, LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026.

AUDIT-RELATEDMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%
FOR: 46,298,319AGAINST: 5,279

Dianthus Therapeutics, Inc.’s own tally for this item (“Proposal 3: Ratification of Appointment of Independent Registered Public Accounting Firm The Company's stockholders ratified the appointment of Deloitte & Touche, LLP as the Company's independent registered public accoun”): 46,298,319 for, 5,279 against, per its Form 8-K filed 2026-05-22 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 54,582,749 outstanding shares: 85% for, 0.1% against (85% of the company cast a for/against vote).

The 82 asset managers below cast 100% of the shares they voted on this item FOR (16,056,011 for, 0 against).

FOR 99.9%
FOR: 16,056,011 (99.9%)ABSTAIN: 14,279 (0.1%)
Largest asset managers voting on “TO RATIFY THE APPOINTMENT OF DELOITTE & TOUCHE, LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR T” at Dianthus Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity4,800,1920 00For
Vanguard3,811,7270 10For
T. Rowe Price1,683,5900 00For
BlackRock800,3330 00For
ALGER INSTITUTIONAL FUNDS488,4630 00For
FRANKLIN STRATEGIC SERIES466,7840 00For
State Street424,2570 00For
Charles Schwab305,8830 00For
AllianceBernstein288,4170 00For
ALGER FUNDS II230,3810 00For
MUTUAL FUND SERIES TRUST225,2610 00For
Columbia Threadneedle220,1880 00For
Prudential/PGIM210,0160 00For
AB DISCOVERY GROWTH FUND, INC.203,2480 00For
TIAA196,5170 00For
Equitable189,2560 00For
ALGER FUNDS156,3410 00For
Dimensional110,8940 00For
Invesco90,1390 00For
Hartford79,2190 00For
American Century78,5320 00For
Lord Abbett71,6350 00For
Principal65,1250 00For
Russell Investments63,6440 00For
QUANTITATIVE MASTER SERIES LLC58,2660 00For

Showing the 25 largest of 82 asset managers. See all 82 in the interactive database.

Largest Dianthus Therapeutics, Inc. shareholders voting in 2025-2026

Ranked by the number of Dianthus Therapeutics, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 54,582,749 shares outstanding at the time of that meeting.

Top Dianthus Therapeutics, Inc. shareholders by shares voted, 2025-2026
#Asset manager % of shares outstanding
1Fidelity 20.31%
2Vanguard 7.53%
3T. Rowe Price 7.27%
4RA CAPITAL MANAGEMENT, L.P. 4.78%
5Fairmount Funds Management LLC 4.65%
6BlackRock 3.95%
7Wellington 3.91%
8Octagon Capital Advisors LP 3.82%
9Polar Capital Holdings Plc 3.48%
10Venrock Adviser, LLC 2.16%

Reported Dianthus Therapeutics, Inc. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

Dianthus Therapeutics, Inc. beneficial owners on record for the 2025-2026 proxy season
Holder % outstanding Disclosure
FMR (Fidelity) 14.23% 13F
BlackRock 5.82% 13F
RA Capital Management, L.P. 4.78% 13G
Wellington Management 4.76% 13F
Vanguard Group 3.75% 13F
Citadel Advisors 3.02% 13F
State Street 2.56% 13F
T. Rowe Price 2.10% 13F
Franklin Templeton 1.77% 13F
Geode Capital 1.68% 13F

Percentages above are of 54,582,749 shares outstanding, as reported by Dianthus Therapeutics, Inc. on its Form 10-Q dated 2026-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Dianthus Therapeutics, Inc.’s 10-Q dated 2026-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At Dianthus Therapeutics, Inc.'s shareholder meeting held 2026-05-21, in the 2025-2026 proxy season, 265 asset managers reported how they voted on 5 ballot items in their SEC Form N-PX filings, covering 1,667 separate fund positions. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation paid to our named executive officers; and — FOR was 96% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Dianthus Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-05-22.

Dianthus Therapeutics, Inc. proxy season coverage: 2024-2025 · 2025-2026 (this page).